56850 Federal Register / Vol. 73, No. 190 / Tuesday, September 30, 2008 / Notices 

deaths caused by cancer in 2008. A 

major drawback of the current 

chemotherapy-based therapeutics is the 

cytotoxic side-effects associated with 

them. Thus there is a dire need to 

develop new therapeutic strategies with 

fewer side-effects. Immuno-therapy has 

taken a lead among the new therapeutic 

approaches. Enhancing the innate 

immune response of an individual has 

been a key approach for the treatment 

against different diseases such as cancer 

and infectious diseases. 

This technology involves the 

generation of novel chemoattractant 

toxins that deplete the T regulatory cells 

(Treg) or other immunosuppressive or 

hyperactivated cells locally. Treg 

controls activation of immune responses 

by suppressing the induction of 

adaptive immune responses, 

particularly T cell responses. 

Immunosuppressive cells such as tumor 

infiltrating macrophages or NKT and 

other cells down regulate antitumor 

immune responses. The chemoattractant 

toxins consist of a toxin moiety fused 

with a chemokine receptor ligand, 

chemokines and other chemoattractants 

that enables specific targeting and 

delivery to the Treg cells. This 

technology is advantageous over the 

more harmful antibodies and chemicals 

that are currently used for the systemic 

depletion of Treg cells. The current 

technology can be used therapeutically 

in a variety of ways. They can be used 

together with vaccines to increase 

efficacy of the vaccine for the treatment 

of cancer, and can be used to locally 

deplete Treg cells or other immuno 

suppressive cells to induce cytolytic cell 

responses at the tumor site or to 

eliminate chronic infectious diseases 

such as HIV and tuberculosis. 

Applications: 

• New chemoattractant based toxins 

targeted towards Treg cells. 

• New chemoattractant based toxins 

targeted towards immunosuppressive 

NKT, and macrophages. 

• New chemoattractant based toxins 

targeted towards local depletion of 

hyperactivated CD4 T cells to treat 

autoimmune diseases. 

• Chemoattractant based toxins 

depleting Treg cells or other 

immunosuppressive cells causing 

enhanced vaccine immune responses. 

• Novel immunotherapy by 

increasing vaccine efficacy against 

cancer and infectious diseases. 

Market: 

• 565,650 deaths from cancer related 

diseases estimated in 2008. 

• The technology platform involving 

novel chemo-attractant based toxins can 

be used to improve vaccine immune 

responses. The cancer vaccine market is 

expected to increase from $135 million 

in 2007 to more than $8 billion in 2012. 

• The technology platform has 

additional market in treating several 

other clinical problems such as 

autoimmune diseases. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Arya Biragyn (NIA), Dolgor 

Bataar (NIA), et al. 

Related Publications: 

1. Copy of manuscript from this 

technology can be provided once 

accepted for publication. 

2. M Coscia, A Biragyn. Cancer 

immunotherapy with chemoattractant 

peptides. Semin Cancer Biol 2004 

Jun;14(3):209–218. 

3. R Schiavo et al. Chemokine 

receptor targeting efficiently directs 

antigens to MHC class I pathways and 

elicits antigen-specific CD8+ T-cell 

responses. Blood 2006 Jun 15;107 

(12):4597–4605. 

Patent Status: U.S. Patent Application 

filed 28 Mar 2008, claiming priority to 

30 Sep 2005 (HHS Reference No. 

E–027–2005/0–US–06). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301–435–4633; wongje@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIA Laboratory of Immunology is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize 

novel chemoattractant-based toxins. 

Please contact John D. Hewes, Ph.D. at 

301–435–3121 or hewesj@mail.nih.gov 

for more information. 

Dated: September 18, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–22889 Filed 9–29–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Review of 

Education and Career Development Award 

Applications. 

Date: October 24, 2008. 

Time: 10 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sheraton Sand Key Resort, 1160 

Gulf Boulevard, Clearwater, FL 33767. 

Contact Person: Robert Bird, PhD, 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Boulevard, Room 

8113, Bethesda, MD 20892–8328, 301–496– 

7978, birdr@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Cancer 

Prevention Research Small Grant Program 

(R03). 

Date: October 30–31, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Renaissance M Street Hotel, Marriot, 

1143 New Hampshire Avenue NW., 

Washington, DC 20037. 

Contact Person: Irina Gordienko, PhD, 

Scientific Review Officer, Scientific Review 

and Logistics Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

6116 Executive Blvd., Rm. 7073, Bethesda, 

MD 20892, 301–594–1566, 

gordienkoiv@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Community Clinical Oncology Program 

(CCOP). 

Date: November 5, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Gerald G. Lovinger, PhD, 

Scientific Review Administrator, Special 

Review and Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8101, 

Bethesda, MD 20892–8329, 301–496–7987, 

lovingeg@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 


ebenthall on PROD1PC60 with NOTICES
Federal Register / Vol. 73, No. 190 / Tuesday, September 30, 2008 / Notices 56851 

Dated: September 23, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–22921 Filed 9–29–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group, Digestive Diseases and 

Nutrition C Subcommittee. 

Date: October 15–16, 2008. 

Open: October 15, 2008, 8 a.m. to 8:30 a.m. 

Agenda: To review procedures and discuss 

policy. 

Place: Crowne Plaza Washington National 

Airport, 1480 Jefferson Davis Hwy, Arlington, 

VA 22202. 

Closed: October 15, 2008, 8:30 a.m. to 5 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Crowne Plaza Washington National 

Airport, 1480 Jefferson Davis Hwy, Arlington, 

VA 22202. 

Closed: October 16, 2008, 8 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Crowne Plaza Washington National 

Airport, 1480 Jefferson Davis Hwy, Arlington, 

VA 22202. 

Contact Person: Dan E. Matsumoto, PhD, 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 749, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8894, 

matsumotod@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group, Diabetes, 

Endocrinology and Metabolic Diseases B 

Subcommittee. 

Date: October 21–23, 2008. 

Open: October 21, 2008, 4 p.m. to 5 p.m. 

Agenda: To review procedures and discuss 

policy. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Closed: October 22, 2008, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Closed: October 23, 2008, 8 a.m. to 5p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: John F. Connaughton, PhD, 

Chief, Chartered Committees Section, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 753, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, 

(301)594–7797, 

connaughtonj@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group; Kidney, Urologic and 

Hematologic Diseases D Subcommittee. 

Date: October 22–23, 2008. 

Open: October 22, 2008, 8 a.m. to 8:30 a.m. 

Agenda: To review procedures and discuss 

policy. 

Place: Gaithersburg Marriott 

Washingtonian Center, 9751 Washingtonian 

Boulevard, Gaithersburg, MD 20878. 

Closed: October 22, 2008, 8:30 a.m. to 5 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Marriott 

Washingtonian Center, 9751 Washingtonian 

Boulevard, Gaithersburg, MD 20878. 

Closed: October 23, 2008, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Marriott 

Washingtonian Center, 9751 Washingtonian 

Boulevard, Gaithersburg, MD 20878. 

Contact Person: Barbara A Woynarowska, 

PhD, Scientific Review Administrator, 

Review Branch, DEA, NIDDK, National 

Institutes of Health, Room 754, 6707 

Democracy Boulevard, Bethesda, MD 20892– 

5452, (301) 402–7172, 

woynarowskab@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: September 19, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–22892 Filed 9–29–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Iron / Malaria. 

Date: October 22, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Rita Anand, PhD., 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health, and Human Development, NIH, 6100 

Executive Blvd. Room 5B01, Bethesda, MD 

20892, (301) 496–1487, 

anandr@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: September 19, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–22894 Filed 9–29–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 


ebenthall on PROD1PC60 with NOTICES